建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
07.31 2023
IBI302 is advancing to Phase III clinical trial by Innovent Biologics
The global development rights for IBI302 have been licensed to Innovent Biologics INC (1801.HK).
07.31 2023
IBI302 is advancing to Phase III clinical trial by Innovent Biologics
The global development rights for IBI302 have been licensed to Innovent Biologics INC (1801.HK).
建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
